<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02571153</url>
  </required_header>
  <id_info>
    <org_study_id>PUCSP 057539/2015</org_study_id>
    <nct_id>NCT02571153</nct_id>
  </id_info>
  <brief_title>Low Doses of Ketamine and Postoperative Quality of Recovery</brief_title>
  <official_title>Effects of Low Doses of Ketamine on Postoperative Quality of Recovery After Total Intravenous Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidade Catolica de Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pontificia Universidade Catolica de Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are evidences that intraoperative administration of low doses of ketamine may
      contribute to control the postoperative pain by acting on the N-methyl-D-aspartate (NMDA)
      channel, reducing the effects related to the tolerance and hyperalgesia induced by opioids.
      This study aims to evaluate the effects of administration of this agent not only as an
      analgesic but also its role in the quality of recovery from anesthesia, which includes
      observation of emotional, psychological and physical aspects. Patients who were scheduled to
      undergo total intravenous anesthesia (TIVA) for laparoscopic cholecystectomy will be enrolled
      in this clinical study. After induction of anesthesia, patients will receive one of three
      solutions according to the randomly selected group: ketamine 0,2 mg/kg; ketamine 0,4 mg/kg or
      saline. In the recovery room and on the ward, data related to the presence of pain, analgesic
      consumption, the incidence of nausea and vomiting, dizziness or hallucinations will be
      recorded. The next day, the quality of recovery will be evaluated by application of the
      questionnaire QoR40 (Quality of Recovery Questionnaire-40).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction It is known that nociceptive stimuli, triggered by surgery and tissue
      inflammation can cause peripheral sensitization and primary hyperalgesia, increases spinal
      responsiveness to stimuli, whether harmful or not, due to the wind-up phenomenon, and other
      mechanisms, with induction central sensitization. Additionally, opioids commonly employed
      during general anesthesia may activate, both, the antinociceptive system and the
      pro-nociceptive system which can lead to acute tolerance and hyperalgesia. There is evidence
      that NMDA receptors are involved in the development of these changes and that low doses of
      ketamine (&lt; 1mg/kg) may control of postoperative pain to bind to the receptor phencyclidine
      the NMDA channel and inhibit the activation of the channel by glutamate non-competitively.
      Recently, there has been a change in pain management, which includes the observation of
      non-traditional variables such as those related to the concepts of satisfaction and quality
      of life related to health. To this end, a growing number of authors went on to assess the
      opinion of patients as a way to determine the quality of recovery from anesthesia, meaning
      the observation not only of pain intensity, but also aspects related to emotional state,
      comfort and independence physical. The QoR-40 questionnaire (Quality of recovery-40), a
      validated instrument for this purpose, allows an objective approach of these factors that can
      influence the perception of the patient and allows you to compare different therapeutic ways.
      There are no recent data on the application of this instrument to assess the effects of
      giving, or not, of low doses of ketamine on the quality of recovery of patients undergoing
      total intravenous anesthesia.

      Methods After arrival in the operating room, standard American Society of Anesthesiologists
      (ASA) monitors will be applied. Midazolam 0.06 mg/kg and 1% lidocaine (30 mg) will be
      administered intravenously immediately after venoclysis. After anesthesia induction,
      capnographic monitoring will be added and the neuromuscular blockade will be evaluated using
      acceleromyography (TOF Watch). Induction and maintenance of anesthesia will be performed as
      follows: remifentanil, induction dose 0.5 μg/kg/min, followed by a maintenance dose of 0.3
      μg/kg/min. Propofol, initial bolus (2.0 mg/kg) followed by infusion at 4 to 6 mg/kg/h. Each
      patient will receive rocuronium (0.6 mg/kg) before tracheal intubation. Ventilation will be
      controlled by adjusting the flow volume and respiratory rate to keep the end-tidal carbon
      dioxid (CO2) level between 30 and 40 mmHg. In the case of inadequate depth of anesthesia
      (movements, sweating, tachycardia, blood pressure increase &gt;10% of the pre-induction value),
      propofol infusion or sevoflurane rate will be increased (by 1%); if this was not sufficient,
      the remifentanil infusion rate will be also increased (by 0,1 μg/kg/min). Patients who
      exhibit reductions in systolic arterial pressure (SAP) greater than 30% or heart rate (HR)
      reductions to less than 50 bpm will be given ephedrine (10 mg) and atropine (0.5 mg),
      respectively. After induction patients will receive one of three intravenous solutions:
      ketamine 0.2 mg/kg - diluted in saline until the volume of 5 mililiters (mL) (k2 group);
      ketamine 0.4 mg/kg diluted in saline until the volume of 5 ml (k4 group) or 5mL of 0.9%
      normal saline (K0 group). Hydration will be maintained with 0.9% normal saline 2 ml/kg/h. All
      of the participants were given dexamethasone (8 mg) and ketoprofen (100 mg) at the onset of
      surgery and dimenhydrinate (30 mg), dipyrone (1 g) and morphine (0.1 mg/kg) 15 minutes prior
      the end of the procedure. Atropine (0.01 mg/kg) and neostigmine (0.05 mg/kg) were used to
      achieve T4/T1&gt;0.9 on the TOF monitor. Extubation was performed after awakening. When stable
      vital signs and respiration was confirmed, all patients were transferred to the
      postanesthesia care unit (PACU). Data related to the occurrence of pain, nausea, vomiting,
      dizziness or hallucinations at the PACU will be recorded as will be the length of stay in the
      PACU. Pain will be assessed every 15 minutes using a 0-10 numeric pain rating scale, where
      zero meant no pain and 10 the worst imaginable pain. Morphine (1 to 2 mg) will be
      administered intravenously every 10 minutes to maintain the pain score below 4 (1 mg when the
      pain score was &lt;7 and 2 mg when it was ≥7). Following discharge from the PACU (minimum stay
      60 minutes and Aldrete &amp; Kroulik index &gt;9), all of the participants will be given ketoprofen
      (100 mg) every 12 hours and dipyrone (30 mg/kg, maximum 1 g) every six hours intravenously.
      Whenever patients judged that their analgesia was insufficient, tramadol (100 mg) will be
      administered intravenously at eight-hour minimum intervals as needed. Postoperative nausea
      and vomiting (PONV) will be treated with dimenhydrinate (30 mg) intravenously. Pain score,
      use of analgesics, and the occurrence of nausea, vomiting, and other complications during the
      hospital ward stay will be recorded.

      QoR40 The quality of postoperative functional recovery will be assessed by the QoR40
      questionnaire, which assesses five dimensions of recovery (physical comfort - 12 items;
      emotional state - 7 items; physical independence - 5 items; physiological support - 7 items;
      and pain - 7 items). Each item is rated on a five-point Likert scale: none of the time, some
      of the time, usually, most of the time, and all the time. The total score on the QoR40 ranges
      from 40 (poorest quality of recovery) to 200 (best quality of recovery). The QoR40 will be
      administered by a blind investigator 24 hours after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Postoperative Recovery Assessed by QoR-40 Questionnaire 24 Hours After Surgery</measure>
    <time_frame>24 hours</time_frame>
    <description>Quality of postoperative functional recovery assessed by the questionnaire QoR40 The quality of postoperative functional recovery was assessed by the QoR-40 questionnaire, which assesses five dimensions of recovery (physical comfort - 12 items; emotional state - 7 items; physical independence - 5 items; physiological support - 7 items; and pain - 7 items). Each item was rated on a five-point Likert scale: none of the time, some of the time, usually, most of the time, and all the time. The total score on the QoR-40 ranges from 40 (poorest quality of recovery) to 200 (best quality of recovery). The QoR-40 was administered by a blind investigator 24 hours after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of PACU Stay</measure>
    <time_frame>During the stay at postanesthesia recovery room (about 90 to 120 minutes)</time_frame>
    <description>Length of stay at postanesthesia recovery room</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Postoperative, Nausea and Vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>Percentage of participants with postoperative nausea and vomiting at the PACU and during the hospital ward stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Pain at PACU Using a 0-10 Numeric Pain Rating Scale</measure>
    <time_frame>90 minutes postanesthesia at recovery room</time_frame>
    <description>Occurrence of pain at the PACU. Average Pain will be calculated. The pain score will be evaluated using a 0-10 numeric pain rating scale, where zero mean no pain and 10 the worst imaginable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine Consumption (mg) at PACU</measure>
    <time_frame>During the stay at postanesthesia recovery room (about 90 to 120 minutes)</time_frame>
    <description>Morphine consumption (mg) at PACU (about 90 to 120 minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Severity of Postoperative Pain</measure>
    <time_frame>24 hours</time_frame>
    <description>The severity of postoperative pain was rated the higher score of pain (NRS) during the hospital ward stay.
Pain was evaluated using a 0-10 numeric pain rating scale (NRS), where zero meant no pain and 10 the worst imaginable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Tramadol Consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Percentage of Participants with Tramadol during the ward stay</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Saline group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 0.9% (5 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ketamine 0.2 mg/kg (5 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0.4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ketamine 0.4 mg/kg (5 mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0.4 mg/kg</intervention_name>
    <description>Intravenous ketamine 0.4 mg/kg after induction of anesthesia</description>
    <arm_group_label>Ketamine 0.4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Intravenous normal saline 0.9% 5 mL</description>
    <arm_group_label>Saline group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0.2 mg/kg</intervention_name>
    <description>Intravenous ketamine 0.2 mg/kg after induction of anesthesia</description>
    <arm_group_label>Ketamine 0.2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists physical status I or II

          -  Patients scheduled to undergo laparoscopic cholecystectomy

        Exclusion Criteria:

          -  Patients who refuse to participate in the study

          -  Patients who are not able to communicate due to alterations in the level of
             consciousness, or neurologic, or psychiatric disease

          -  Contraindication of any of the drugs used in the study

          -  Patients who are superobese (BMI&gt;40)

          -  History of alcohol or drug dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo T Moro, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Medical and Health Sciences, Pontificial Catholic University of São Paulo - PUCSP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Santa Lucinda Hospital</name>
      <address>
        <city>Sorocaba</city>
        <state>SP</state>
        <zip>18030-230</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Xie H, Wang X, Liu G, Wang G. Analgesic effects and pharmacokinetics of a low dose of ketamine preoperatively administered epidurally or intravenously. Clin J Pain. 2003 Sep-Oct;19(5):317-22.</citation>
    <PMID>12966258</PMID>
  </reference>
  <reference>
    <citation>Myles PS, Weitkamp B, Jones K, Melick J, Hensen S. Validity and reliability of a postoperative quality of recovery score: the QoR-40. Br J Anaesth. 2000 Jan;84(1):11-5.</citation>
    <PMID>10740540</PMID>
  </reference>
  <reference>
    <citation>Wu L, Huang X, Sun L. The efficacy of N-methyl-D-aspartate receptor antagonists on improving the postoperative pain intensity and satisfaction after remifentanil-based anesthesia in adults: a meta-analysis. J Clin Anesth. 2015 Jun;27(4):311-24. doi: 10.1016/j.jclinane.2015.03.020. Epub 2015 Mar 29.</citation>
    <PMID>25824051</PMID>
  </reference>
  <reference>
    <citation>Pfenninger EG, Durieux ME, Himmelseher S. Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. Anesthesiology. 2002 Feb;96(2):357-66.</citation>
    <PMID>11818769</PMID>
  </reference>
  <reference>
    <citation>Kissin I, Bright CA, Bradley EL Jr. The effect of ketamine on opioid-induced acute tolerance: can it explain reduction of opioid consumption with ketamine-opioid analgesic combinations? Anesth Analg. 2000 Dec;91(6):1483-8.</citation>
    <PMID>11094005</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <results_first_submitted>September 28, 2016</results_first_submitted>
  <results_first_submitted_qc>January 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2017</results_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pontificia Universidade Catolica de Sao Paulo</investigator_affiliation>
    <investigator_full_name>Eduardo Toshiyuki Moro</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Intravenous anesthesia</keyword>
  <keyword>Postoperative nausea vomiting</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Patient satisfaction</keyword>
  <keyword>Quality of health care</keyword>
  <keyword>Ketamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Saline Group</title>
          <description>Normal saline 0.9% (5 mL)
Normal saline: Intravenous normal saline 0.9% 5 mL</description>
        </group>
        <group group_id="P2">
          <title>Ketamine 0.2</title>
          <description>ketamine 0.2 mg/kg (5 mL)
Ketamine 0.2 mg/kg: Intravenous ketamine 0.2 mg/kg after induction of anesthesia</description>
        </group>
        <group group_id="P3">
          <title>Ketamine 0.4</title>
          <description>ketamine 0.4 mg/kg (5 mL)
Ketamine 0.4 mg/kg: Intravenous ketamine 0.4 mg/kg after induction of anesthesia</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Saline Group</title>
          <description>Normal saline 0.9% (5 mL)
Normal saline: Intravenous normal saline 0.9% 5 mL</description>
        </group>
        <group group_id="B2">
          <title>Ketamine 0.2</title>
          <description>ketamine 0.2 mg/kg (5 mL)
Ketamine 0.2 mg/kg: Intravenous ketamine 0.2 mg/kg after induction of anesthesia</description>
        </group>
        <group group_id="B3">
          <title>Ketamine 0.4</title>
          <description>ketamine 0.4 mg/kg (5 mL)
Ketamine 0.4 mg/kg: Intravenous ketamine 0.4 mg/kg after induction of anesthesia</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.8" spread="11.3"/>
                    <measurement group_id="B2" value="47.2" spread="13.3"/>
                    <measurement group_id="B3" value="44.1" spread="11.4"/>
                    <measurement group_id="B4" value="44.3" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quality of Postoperative Recovery Assessed by QoR-40 Questionnaire 24 Hours After Surgery</title>
        <description>Quality of postoperative functional recovery assessed by the questionnaire QoR40 The quality of postoperative functional recovery was assessed by the QoR-40 questionnaire, which assesses five dimensions of recovery (physical comfort – 12 items; emotional state – 7 items; physical independence – 5 items; physiological support - 7 items; and pain – 7 items). Each item was rated on a five-point Likert scale: none of the time, some of the time, usually, most of the time, and all the time. The total score on the QoR-40 ranges from 40 (poorest quality of recovery) to 200 (best quality of recovery). The QoR-40 was administered by a blind investigator 24 hours after surgery.</description>
        <time_frame>24 hours</time_frame>
        <population>Total of 152 patients were first assessed for eligibility in this study; however, 17 were excluded because they refused participation, or met any of the exclusion criteria. Thus, 135 participants were randomly allocated to the study groups. Later, 6 participants in group S, 8 in group K2, and 2 in group K4 were excluded due to protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Saline Group</title>
            <description>Normal saline 0.9% (5 mL)
Normal saline: Intravenous normal saline 0.9% 5 mL</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.2</title>
            <description>ketamine 0.2 mg/kg (5 mL)
Ketamine 0.2 mg/kg: Intravenous ketamine 0.2 mg/kg after induction of anesthesia</description>
          </group>
          <group group_id="O3">
            <title>Ketamine 0.4</title>
            <description>ketamine 0.4 mg/kg (5 mL)
Ketamine 0.4 mg/kg: Intravenous ketamine 0.4 mg/kg after induction of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Postoperative Recovery Assessed by QoR-40 Questionnaire 24 Hours After Surgery</title>
          <description>Quality of postoperative functional recovery assessed by the questionnaire QoR40 The quality of postoperative functional recovery was assessed by the QoR-40 questionnaire, which assesses five dimensions of recovery (physical comfort – 12 items; emotional state – 7 items; physical independence – 5 items; physiological support - 7 items; and pain – 7 items). Each item was rated on a five-point Likert scale: none of the time, some of the time, usually, most of the time, and all the time. The total score on the QoR-40 ranges from 40 (poorest quality of recovery) to 200 (best quality of recovery). The QoR-40 was administered by a blind investigator 24 hours after surgery.</description>
          <population>Total of 152 patients were first assessed for eligibility in this study; however, 17 were excluded because they refused participation, or met any of the exclusion criteria. Thus, 135 participants were randomly allocated to the study groups. Later, 6 participants in group S, 8 in group K2, and 2 in group K4 were excluded due to protocol deviations.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.8" lower_limit="177.4" upper_limit="198.2"/>
                    <measurement group_id="O2" value="189.6" lower_limit="177.6" upper_limit="201.6"/>
                    <measurement group_id="O3" value="186.8" lower_limit="175.5" upper_limit="198.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of PACU Stay</title>
        <description>Length of stay at postanesthesia recovery room</description>
        <time_frame>During the stay at postanesthesia recovery room (about 90 to 120 minutes)</time_frame>
        <population>Patients aged 18 to 65 years old, with an ASA physical status I or II, who would be scheduled to undergo laparoscopic cholecystectomy.</population>
        <group_list>
          <group group_id="O1">
            <title>Saline Group</title>
            <description>Normal saline 0.9% (5 mL)
Normal saline: Intravenous normal saline 0.9% 5 mL</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.2</title>
            <description>ketamine 0.2 mg/kg (5 mL)
Ketamine 0.2 mg/kg: Intravenous ketamine 0.2 mg/kg after induction of anesthesia</description>
          </group>
          <group group_id="O3">
            <title>Ketamine 0.4</title>
            <description>ketamine 0.4 mg/kg (5 mL)
Ketamine 0.4 mg/kg: Intravenous ketamine 0.4 mg/kg after induction of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Length of PACU Stay</title>
          <description>Length of stay at postanesthesia recovery room</description>
          <population>Patients aged 18 to 65 years old, with an ASA physical status I or II, who would be scheduled to undergo laparoscopic cholecystectomy.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.9" lower_limit="59.2" upper_limit="106.6"/>
                    <measurement group_id="O2" value="84.5" lower_limit="68" upper_limit="101"/>
                    <measurement group_id="O3" value="86" lower_limit="52.1" upper_limit="119.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Postoperative, Nausea and Vomiting</title>
        <description>Percentage of participants with postoperative nausea and vomiting at the PACU and during the hospital ward stay</description>
        <time_frame>24 hours</time_frame>
        <population>Patients aged 18 to 65 years old, with an ASA physical status I or II, who would be scheduled to undergo laparoscopic cholecystectomy.</population>
        <group_list>
          <group group_id="O1">
            <title>Saline Group</title>
            <description>Normal saline 0.9% (5 mL)
Normal saline: Intravenous normal saline 0.9% 5 mL</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.2</title>
            <description>ketamine 0.2 mg/kg (5 mL)
Ketamine 0.2 mg/kg: Intravenous ketamine 0.2 mg/kg after induction of anesthesia</description>
          </group>
          <group group_id="O3">
            <title>Ketamine 0.4</title>
            <description>ketamine 0.4 mg/kg (5 mL)
Ketamine 0.4 mg/kg: Intravenous ketamine 0.4 mg/kg after induction of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Postoperative, Nausea and Vomiting</title>
          <description>Percentage of participants with postoperative nausea and vomiting at the PACU and during the hospital ward stay</description>
          <population>Patients aged 18 to 65 years old, with an ASA physical status I or II, who would be scheduled to undergo laparoscopic cholecystectomy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="29.7"/>
                    <measurement group_id="O3" value="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Pain at PACU Using a 0-10 Numeric Pain Rating Scale</title>
        <description>Occurrence of pain at the PACU. Average Pain will be calculated. The pain score will be evaluated using a 0-10 numeric pain rating scale, where zero mean no pain and 10 the worst imaginable pain.</description>
        <time_frame>90 minutes postanesthesia at recovery room</time_frame>
        <population>Patients aged 18 to 65 years old, with an ASA physical status I or II, who would be scheduled to undergo laparoscopic cholecystectomy.</population>
        <group_list>
          <group group_id="O1">
            <title>Saline Group</title>
            <description>Normal saline 0.9% (5 mL)
Normal saline: Intravenous normal saline 0.9% 5 mL</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.2</title>
            <description>ketamine 0.2 mg/kg (5 mL)
Ketamine 0.2 mg/kg: Intravenous ketamine 0.2 mg/kg after induction of anesthesia</description>
          </group>
          <group group_id="O3">
            <title>Ketamine 0.4</title>
            <description>ketamine 0.4 mg/kg (5 mL)
Ketamine 0.4 mg/kg: Intravenous ketamine 0.4 mg/kg after induction of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Pain at PACU Using a 0-10 Numeric Pain Rating Scale</title>
          <description>Occurrence of pain at the PACU. Average Pain will be calculated. The pain score will be evaluated using a 0-10 numeric pain rating scale, where zero mean no pain and 10 the worst imaginable pain.</description>
          <population>Patients aged 18 to 65 years old, with an ASA physical status I or II, who would be scheduled to undergo laparoscopic cholecystectomy.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.2" upper_limit="7.4"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0" upper_limit="5.8"/>
                    <measurement group_id="O3" value="2.8" lower_limit="0" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morphine Consumption (mg) at PACU</title>
        <description>Morphine consumption (mg) at PACU (about 90 to 120 minutes)</description>
        <time_frame>During the stay at postanesthesia recovery room (about 90 to 120 minutes)</time_frame>
        <population>Patients aged 18 to 65 years old, with an ASA physical status I or II, who would be scheduled to undergo laparoscopic cholecystectomy.</population>
        <group_list>
          <group group_id="O1">
            <title>Saline Group</title>
            <description>Normal saline 0.9% (5 mL)
Normal saline: Intravenous normal saline 0.9% 5 mL</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.2</title>
            <description>ketamine 0.2 mg/kg (5 mL)
Ketamine 0.2 mg/kg: Intravenous ketamine 0.2 mg/kg after induction of anesthesia</description>
          </group>
          <group group_id="O3">
            <title>Ketamine 0.4</title>
            <description>ketamine 0.4 mg/kg (5 mL)
Ketamine 0.4 mg/kg: Intravenous ketamine 0.4 mg/kg after induction of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Morphine Consumption (mg) at PACU</title>
          <description>Morphine consumption (mg) at PACU (about 90 to 120 minutes)</description>
          <population>Patients aged 18 to 65 years old, with an ASA physical status I or II, who would be scheduled to undergo laparoscopic cholecystectomy.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0" upper_limit="3.7"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0" upper_limit="2.4"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Severity of Postoperative Pain</title>
        <description>The severity of postoperative pain was rated the higher score of pain (NRS) during the hospital ward stay.
Pain was evaluated using a 0-10 numeric pain rating scale (NRS), where zero meant no pain and 10 the worst imaginable pain.</description>
        <time_frame>24 hours</time_frame>
        <population>Patients aged 18 to 65 years old, with an ASA physical status I or II, who would be scheduled to undergo laparoscopic cholecystectomy.</population>
        <group_list>
          <group group_id="O1">
            <title>Saline Group</title>
            <description>Normal saline 0.9% (5 mL)
Normal saline: Intravenous normal saline 0.9% 5 mL</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.2</title>
            <description>ketamine 0.2 mg/kg (5 mL)
Ketamine 0.2 mg/kg: Intravenous ketamine 0.2 mg/kg after induction of anesthesia</description>
          </group>
          <group group_id="O3">
            <title>Ketamine 0.4</title>
            <description>ketamine 0.4 mg/kg (5 mL)
Ketamine 0.4 mg/kg: Intravenous ketamine 0.4 mg/kg after induction of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>The Severity of Postoperative Pain</title>
          <description>The severity of postoperative pain was rated the higher score of pain (NRS) during the hospital ward stay.
Pain was evaluated using a 0-10 numeric pain rating scale (NRS), where zero meant no pain and 10 the worst imaginable pain.</description>
          <population>Patients aged 18 to 65 years old, with an ASA physical status I or II, who would be scheduled to undergo laparoscopic cholecystectomy.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0.4" upper_limit="6"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0" upper_limit="5.5"/>
                    <measurement group_id="O3" value="3.6" lower_limit="0.5" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Tramadol Consumption</title>
        <description>Percentage of Participants with Tramadol during the ward stay</description>
        <time_frame>24 hours</time_frame>
        <population>Patients aged 18 to 65 years old, with an ASA physical status I or II, who would be scheduled to undergo laparoscopic cholecystectomy.</population>
        <group_list>
          <group group_id="O1">
            <title>Saline Group</title>
            <description>Normal saline 0.9% (5 mL)
Normal saline: Intravenous normal saline 0.9% 5 mL</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.2</title>
            <description>ketamine 0.2 mg/kg (5 mL)
Ketamine 0.2 mg/kg: Intravenous ketamine 0.2 mg/kg after induction of anesthesia</description>
          </group>
          <group group_id="O3">
            <title>Ketamine 0.4</title>
            <description>ketamine 0.4 mg/kg (5 mL)
Ketamine 0.4 mg/kg: Intravenous ketamine 0.4 mg/kg after induction of anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Tramadol Consumption</title>
          <description>Percentage of Participants with Tramadol during the ward stay</description>
          <population>Patients aged 18 to 65 years old, with an ASA physical status I or II, who would be scheduled to undergo laparoscopic cholecystectomy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="10.8"/>
                    <measurement group_id="O3" value="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Saline Group</title>
          <description>Normal saline 0.9% (5 mL)
Normal saline: Intravenous normal saline 0.9% 5 mL</description>
        </group>
        <group group_id="E2">
          <title>Ketamine 0.2</title>
          <description>ketamine 0.2 mg/kg (5 mL)
Ketamine 0.2 mg/kg: Intravenous ketamine 0.2 mg/kg after induction of anesthesia</description>
        </group>
        <group group_id="E3">
          <title>Ketamine 0.4</title>
          <description>ketamine 0.4 mg/kg (5 mL)
Ketamine 0.4 mg/kg: Intravenous ketamine 0.4 mg/kg after induction of anesthesia</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eduardo Toshiyuki Moro</name_or_title>
      <organization>Pontificia UCSP</organization>
      <email>eduardo_moro@terra.com.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

